Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses

Science Translational Medicine

Volumn 8, Issue 334, 2016, Pages

  Welters, Marij J ^a   Van Der Sluis, Tetje C ^a   Van Meir, Hélène ^a,b   Loof, Nikki M ^a   Van Ham, Vanessa J ^a   Van Duikeren, Suzanne ^a   Santegoets, Saskia J ^a   Arens, Ramon ^a   De Kam, Marieke L ^b   Cohen, Adam F ^b   Van Poelgeest, Mariette I ^a   Kenter, Gemma G ^c   Kroep, Judith R ^a   Burggraaf, Jacobus ^b   Melief, Cornelis J ^a,d   Van Der Burg, Sjoerd H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ISA Pharmaceuticals   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GAMMA INTERFERON; HUMAN PAPILLOMAVIRUS TYPE 16 OVERLAPPING SYNTHETIC PEPTIDE; INTERLEUKIN 2; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WART VIRUS VACCINE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW CELL; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; INJECTION SITE REACTION; INJECTION SITE ULCER; LEUKOPENIA; LYMPHOCYTE PROLIFERATION; MOUSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OBSERVATIONAL STUDY; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; ANIMAL; C57BL MOUSE; CELL COUNT; CELL MOTION; CLINICAL TRIAL; DRUG EFFECTS; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MONONUCLEAR CELL; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIROLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL COUNT; CELL MOVEMENT; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNITY; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; MICE, INBRED C57BL; MYELOID CELLS; T-LYMPHOCYTES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84963864932     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad8307     Document Type: Review

References (35)

1. G. Y. F. Ho, A. S. Kadish, R. D. Burk, J. Basu, P. R. Palan, M. Mikhail, S. L. Romney, HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int. J. Cancer 78, 281-285 (1998).
2. T. W. Burke, W. J. Hoskins, P. B. Heller, M. C. Shen, E. B. Weiser, R. C. Park, Clinical patterns of tumor recurrence after radical hysterectomy in stage IB cervical carcinoma. Obstet. Gynecol. 69, 382-385 (1987).
3. D. M. Larson, L. J. Copeland, C. A. Stringer, D. M. Gershenson, J. M. Malone Jr., C. L. Edwards, Recurrent cervical carcinoma after radical hysterectomy. Gynecol. Oncol. 30, 381-387 (1988).
4. B. J. Monk, M. W. Sill, D. S. McMeekin, D. E. Cohn, L. M. Ramondetta, C. H. Boardman, J. Benda, D. Cella, Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study. J. Clin. Oncol. 27, 4649-4655 (2009).
5. D. Lorusso, F. Petrelli, A. Coinu, F. Raspagliesi, S. Barni, A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol. Oncol. 133, 117-123 (2014).
6. H. zur Hausen, Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2, 342-350 (2002).
7. S. H. van der Burg, C. J. Melief, Therapeutic vaccination against human papilloma virus induced malignancies. Curr. Opin. Immunol. 23, 252-257 (2011).
8. G. G. Kenter, M. J. P.Welters, A. R. P.M. Valentijn, M. J.G. Lowik, D. M.A. Berends-van der Meer, A. P. G. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, A. R. Wafelman, J. Oostendorp, G. J. Fleuren, S. H. van der Burg, C. J. M. Melief, Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838-1847 (2009).
9. M. J. P. Welters, G. G. Kenter, P. J. de Vos van Steenwijk, M. J. G. Löwik, D. M. A. Berends-van der Meer, F. Essahsah, L. F. M. Stynenbosch, A. P. G. Vloon, T. H. Ramwadhdoebe, S. J. Piersma, J. M. van der Hulst, A. R. P. M. Valentijn, L. M. Fathers, J. W. Drijfhout, K. L. M. C. Franken, J. Oostendorp, G. J. Fleuren, C. J. M. Melief, S. H. van der Burg, Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl. Acad. Sci. U.S.A. 107, 11895-11899 (2010).
10. M. I. E. van Poelgeest, M. J. P. Welters, R. Vermeij, L. F. M. Stynenbosch, N. M. Loof, D.M.A. Berends-van derMeer, M. J.G. Lowik, I. L. E. Hamming, E. M. G. vanEsch, B. W. J.Hellebrekers, M. van Beurden, H.W. Schreuder, M. J. Kagie, J. B.M. Z. Trimbos, L. M. Fathers, T. Daemen, H. Hollema, R. Valentijn, J. Oostendorp, J. H. N. G. Oude Elberink, G. J. Fleuren, T. Bosse, G. G. Kenter, T. Stijnen, H. W. Nijman, C. J. M. Melief, S. H. van der Burg, Vaccination against oncoproteins of HPV16 for non-invasive vulvar/vaginal lesions: Lesion clearance is related to the strength of the T-cell response. Clin. Cancer Res. pii: clincanres.2594.2015 (2016).
11. M. I. E. van Poelgeest, M. J. P. Welters, E. M. G. van Esch, L. F. M. Stynenbosch, G. Kerpershoek, E. L. van Persijn van Meerten, M. van den Hende, M. J. G. Löwik, D. M. A. Berends-van der Meer, L. M. Fathers, A. R. P. M. Valentijn, J. Oostendorp, G. J. Fleuren, C. J. M. Melief, G. G. Kenter, S. H. van der Burg, HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J. Transl. Med. 11, 88 (2013).
12. D. Hanahan, R. A. Weinberg, The hallmarks of cancer. Cell 100, 57-70 (2000).
13. T. C. van der Sluis, S. van Duikeren, S. Huppelschoten, E. S. Jordanova, E. Beyranvand Nejad, A. Sloots, L. Boon, V. T. H. B. M. Smit, M. J. P. Welters, F. Ossendorp, B. van de Water, R. Arens, S. H. van der Burg, C. J. M. Melief, Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death. Clin. Cancer Res. 21, 781-794 (2015).
14. L. Bracci, G. Schiavoni, A. Sistigu, F. Belardelli, Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21, 15-25 (2014).
15. A. K. Nowak, B. W. S. Robinson, R. A. Lake, Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 63, 4490-4496 (2003).
16. Y. Diaz, Y. Tundidor, A. Lopez, K. Leon, Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response. Cancer Immunol. Immunother. 62, 455-469 (2013).
17. S. Walter, T. Weinschenk, A. Stenzl, R. Zdrojowy, A. Pluzanska, C. Szczylik, M. Staehler, W. Brugger, P.-Y. Dietrich, R. Mendrzyk, N. Hilf, O. Schoor, J. Fritsche, A. Mahr, D. Maurer, V. Vass, C. Trautwein, P. Lewandrowski, C. Flohr, H. Pohla, J.J. Stanczak, V. Bronte, S. Mandruzzato, T. Biedermann, G. Pawelec, E. Derhovanessian, H. Yamagishi, T. Miki, F. Hongo, N. Takaha, K. Hirakawa, H. Tanaka, S. Stevanovic, J. Frisch, A. Mayer-Mokler, A. Kirner, H.-G. Rammensee, C. Reinhardt, H. Singh-Jasuja, Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18, 1254-1261 (2012).
18. C. H. Yarbro, Carboplatin: A clinical review. Semin. Oncol. Nurs. 5, 63-69 (1989).
19. J. M. Nabholtz, K. Gelmon, M. Bontenbal, M. Spielmann, G. Catimel, P. Conte, U. Klaassen, M. Namer, J. Bonneterre, P. Fumoleau, B. Winograd, Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol. 14, 1858-1867 (1996).
20. W. C. Rose, J. E. Schurig, Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat. Rev. 12 (Suppl. A), 1-19 (1985).
21. M. Treskes, E. Boven, A. A. van de Loosdrecht, J. F. A. M. Wijffels, J. Cloos, G. J. Peters, H. M. Pinedo, W. J. F. van der Vijgh, Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur. J. Cancer 30, 183-187 (1994).
22. H. Minami, Y. Sasaki, N. Saijo, T. Ohtsu, H. Fujii, T. Igarashi, K. Itoh, Indirect-response model for the time course of leukopenia with anticancer drugs. Clin. Pharmacol. Ther. 64, 511-521 (1998).
23. W. Krzyzanski, W. J. Jusko, Multiple-pool cell lifespan model of hematologic effects of anticancer agents. J. Pharmacokinet. Pharmacodyn. 29, 311-337 (2002).
24. S. Coleman, A. Clayton, M. D. Mason, B. Jasani, M. Adams, Z. Tabi, Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res. 65, 7000-7006 (2005).
25. X. Wu, Q.-M. Feng, Y. Wang, J. Shi, H.-L. Ge, W. Di, The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy. Cancer Immunol. Immunother. 59, 279-291 (2010).
26. S. C. Stone, R. A. M. Rossetti, A. Bolpetti, E. Boccardo, P. S. de Araujo Souza, A. P. Lepique, HPV16-associated tumors control myeloid cell homeostasis in lymphoid organs, generating a suppressor environment for T cells. J. Leukoc. Biol. 96, 619-631 (2014).
27. S. Mabuchi, Y. Matsumoto, F. Isohashi, Y. Yoshioka, H. Ohashi, E. Morii, T. Hamasaki, K. Aozasa, D. G. Mutch, T. Kimura, Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. Gynecol. Oncol. 122, 25-32 (2011).
28. M. T. Yazdi, N.M. Loof, K. L. M. C. Franken, C. Taube, J.Oostendorp, P. S. Hiemstra, M. J. P. Welters, S. H. van der Burg, Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma. Cancer Immunol. Immunother. 64, 1109-1121 (2015).
29. M. Reck, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, R. Chacko, M. Sebastian, H. Lu, J.-M. Cuillerot, T. J. Lynch, Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial. Ann. Oncol. 24, 75-83 (2013).
30. P. J. de Vos van Steenwijk, T. H. Ramwadhdoebe, R. Goedemans, E. M. Doorduijn, J. J. van Ham, A. Gorter, T. van Hall, M. L. Kuijjer, M. I. E. van Poelgeest, S. H. van der Burg, E. S. Jordanova, Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma. Int. J. Cancer 133, 2884-2894 (2013).
31. M. C. A. Wouters, E. M. Dijkgraaf, M. L. Kuijjer, E. S. Jordanova, H. Hollema, M. J. P. Welters, J. J. M. van der Hoeven, T. Daemen, J. R. Kroep, H. W. Nijman, S. H. van der Burg, Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. OncoImmunology 3, e962397 (2014).
32. K.-Y. Lin, F. G. Guarnieri, K. F. Staveley-O'Carroll, H. I. Levitsky, J. T. August, D. M. Pardoll, T.-C. Wu, Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21-26 (1996).
33. A. de Jong, M. I. E. van Poelgeest, J. M. van der Hulst, J. W. Drijfhout, G. J. Fleuren, C. J. M. Melief, G. Kenter, R. Offringa, S. H. van der Burg, Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 64, 5449-5455 (2004).
34. E. M. Dijkgraaf, S. J. A. M. Santegoets, A. K. L. Reyners, R. Goedemans, H.W. Nijman, M.I. E. van Poelgeest, A. R. van Erkel, V.T. H. B. M. Smit, T.A.H.H.Daemen, J. J. M. van der Hoeven, C. J. M. Melief, M. J. P. Welters, J. R. Kroep, S. H. van der Burg, A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget 6, 32228-32243 (2015).
35. G. I. W. G. European Medicines Agency, Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples. 1-19 (2012).